Nantahala Capital Management LLC Purchases Shares of 610,691 DarioHealth Corp. $DRIO

Nantahala Capital Management LLC bought a new stake in DarioHealth Corp. (NASDAQ:DRIO) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 610,691 shares of the company’s stock, valued at approximately $4,030,561. Nantahala Capital Management LLC owned 0.08% of DarioHealth at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of DRIO. Kestra Advisory Services LLC acquired a new stake in DarioHealth in the 4th quarter valued at about $35,000. XTX Topco Ltd grew its position in shares of DarioHealth by 229.0% during the second quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after buying an additional 43,513 shares in the last quarter. BlackRock Inc. acquired a new position in shares of DarioHealth during the second quarter worth about $249,000. Finally, Geode Capital Management LLC grew its position in shares of DarioHealth by 167.9% during the fourth quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock worth $564,000 after buying an additional 31,063 shares in the last quarter. 33.39% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at DarioHealth

In related news, Director Dennis Matheis bought 14,430 shares of the company’s stock in a transaction dated Thursday, July 23rd. The shares were acquired at an average price of $6.93 per share, with a total value of $99,999.90. Following the completion of the acquisition, the director owned 43,026 shares in the company, valued at approximately $298,170.18. This trade represents a 50.46% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.50% of the stock is owned by company insiders.

DarioHealth Price Performance

DRIO stock opened at $6.77 on Friday. The company has a market capitalization of $66.35 million, a P/E ratio of -1.10 and a beta of 1.11. DarioHealth Corp. has a twelve month low of $5.84 and a twelve month high of $17.74. The business has a 50 day simple moving average of $7.09 and a 200-day simple moving average of $7.99. The company has a current ratio of 2.31, a quick ratio of 1.92 and a debt-to-equity ratio of 0.56.

DarioHealth (NASDAQ:DRIO) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.37. DarioHealth had a negative net margin of 169.87% and a negative return on equity of 54.81%. The company had revenue of $5.18 million for the quarter, compared to analyst estimates of $5.92 million. As a group, equities analysts anticipate that DarioHealth Corp. will post -2.94 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Alliance Global Partners began coverage on shares of DarioHealth in a report on Wednesday, August 19th. They set a “buy” rating and a $12.00 price target for the company. Stifel Nicolaus restated a “buy” rating and issued a $10.00 price objective on shares of DarioHealth in a report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DarioHealth in a research report on Friday, July 10th. Finally, TD Cowen lowered their target price on shares of DarioHealth from $11.00 to $8.00 and set a “hold” rating for the company in a research note on Wednesday, August 12th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $10.00.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.